Sjögren's disease & overlap diseases
Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort
Authors' conclusion
B-cell biomarkers profile in SjD is largely stable over time. However, a high baseline 'B-cell burden' identifies patients at risk of poorer outcomes
Study context
- Population
- Patients with primary Sjögren's disease (SjD) fulfilling AECG criteria with ≥2 visits including immunological assessments and ClinESSDAI over 5 years, French ASSESS cohortof 395 ASSESS participants
- Participants
- 362 patients
- Exposure
- Number of abnormal baseline B-cell markers
- Outcome
- Longitudinal evolution of B-cell biomarkers and association with clinical disease course (ClinESSDAI)
Methodological detailsmulticentre, longitudinal, Mean follow-up 56.4 months (±10.6); mean 5.3 visits per patient (±0.5)
- Multicentre
- Longitudinal
- Mean follow-up 56.4 months (±10.6); mean 5.3 visits per patient (±0.5)
Main finding
As reported in the abstract
Stability of B-cell biomarkers
B-cell biomarkers remained stable
80.5%
Biological responders (STAR biological domain, IgG decrease), mostly within first year, no correlation with changes in ClinESSDAI or ESSPRI
43.1%
Risk of persistent or worsening disease with multiple B-cell activity markers, particularly ≥5: OR
4.6
95% CI 1.2–17.8P = 0.002
Observational data: associations, not effects.
Further findings
Baseline ClinESSDAI by number of B-cell abnormalities
- Did not differ (P = 0.096)
Original publication
Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort. Rheumatology (Oxford). Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →